Noble Financial Affirms BioCryst Pharma (BCRX) at 'Buy' Following BCX7353 Phase 1 Update
Tweet Send to a Friend
Noble Financial maintained its Buy rating and $21 price target on BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) after the company announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
